Bacterial translocation from the gut to the distant organs: an overview
Research into triple-agonist peptides such as Retatrutide has expanded significantly since 2020, with published Phase 2 data (Jastreboff et al., 2023, New England Journal of Medicine) indicating substantial effects in human clinical trials on body weight and glycaemic parameters
Nawrocki will prescribe one of our weight loss medicationsSemaglutide or Tirzepatide
As of January 2026, 13 states (Delaware, Kansas, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, North Carolina, Rhode Island, Tennessee, Utah, Virginia, and Wisconsin) cover GLP-1 receptor agonists (such as Wegovy) for weight loss
Metabolic markers
A 2024 Survey of healthcare providers who use GLP-1 Probiotic Pro in their practice revealed that 78% of these providers used the probiotic to help patents naturally support GLP-1 hormone levels, manage food cravings and maintain a healthy weight after stopping GLP-1 medications